Evidence map›Paper›PMID 38106365›Full record

ReviewPatient preference and adherence2023

Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema.

Andrea Taloni, Giulia Coco, Davide Rastelli, Giacinta Buffon, Vincenzo Scorcia, Giuseppe Giannaccare

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Patient preference and adherence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Andrea Taloni *Department of Ophthalmology, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Giulia Coco *Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0002-2410-6366
Davide RastelliDepartment of Ophthalmology, Policlinico Casilino, Rome, Italy.
Giacinta BuffonDepartment of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, Rome, Italy.
Vincenzo ScorciaDepartment of Ophthalmology, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.ORCID 0000-0001-6826-7957
Giuseppe GiannaccareEye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Magna Graecia University · ITUniversity of Rome Tor Vergata · ITPoliclinico Casilino · ITUniversity of Cagliari · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic macular edema (DME) is a common sight-threatening complication of diabetic retinopathy (DR) and the leading cause of severe visual impairment among the working-age population. Several therapeutic options are available for the management of DME, including intravitreal corticosteroids. They have been traditionally used as second-line treatment, due to the risk of intraocular pressure increase and cataract-related adverse events. However, attention has recently been focused on the primary or early use of intravitreal corticosteroids, due to growing evidence of the crucial role of inflammation in the pathogenesis of DME. Furthermore, intravitreal steroid implants offer the additional advantage of a longer duration of action compared to anti-vascular endothelial growth factor agents (anti-VEGF). This review aims to summarize the available evidence on the efficacy and safety profile of dexamethasone (DEX) intravitreal implant, with a specific focus on clinical scenarios in which it might be considered or even preferred as first-line treatment option by adequate selection of patients, considering both advantages and possible adverse events. Patients with contraindications to anti-VEGF, DME with high inflammatory OCT biomarkers, pseudophakic patients and phakic patients' candidates to cataract surgery as well as vitrectomized eyes may all benefit from first-line DEX implant. Additionally, DME not responders to anti-VEGF should be considered for a switch to DEX implant and a combination therapy of DEX implant and anti-VEGF could be a valid option in severe and persistent DME.

Indexed as

corticosteroidsdexamethasone intravitreal implantDEX implantdiabetic macular edemaDMEOzurdex

Identifiers

PMID38106365
PMCPMC10725633
OpenAlexW4389628343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.